Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Andrew Louis Warshaw

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7788-3110; OpenAlex author ID A5009676742, A5113464680. Sources: OpenAlex.

Their work

Papers
41 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
114
Papers, trials and grants by year

2011: 2 papers · 2012: 3 papers · 2013: 3 papers · 2014: none · 2015: 3 papers · 2016: 2 papers · 2017: 2 papers · 2018: 3 papers · 2019: 2 papers · 2020: 9 papers · 2021: 4 papers · 2022: 2 papers · 2023: 2 papers · 2024: 2 papers · 2025: 2 papers

Papers 41

  1. Prognostic factors for very early recurrence after neoadjuvant treatment and curative resection in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2025.109647↗
  2. Collagen XVII Promotes Pancreatic Ductal Adenocarcinoma Tumor Growth through Regulation of PIK3R5. Co-author DOI 10.1158/2767-9764.crc-24-0392↗
  3. The Revised R Status is an Independent Predictor of Postresection Survival in Pancreatic Cancer After Neoadjuvant Treatment. Co-author DOI 10.1097/sla.0000000000005874↗
  4. Dynamic Evolution of Fibroblasts Revealed by Single-Cell RNA Sequencing of Human Pancreatic Cancer. Co-author DOI 10.1158/2767-9764.crc-23-0489↗
  5. Portal Vein or Superior Mesenteric Vein Thrombosis with Dose-Escalated Radiation for Borderline or Locally Advanced Pancreatic Cancer. Co-author DOI 10.1007/s11605-023-05796-5↗
  6. Smoking impairs the effect of neoadjuvant FOLFIRINOX on postresection survival in pancreatic cancer. Co-author DOI 10.1016/j.ejca.2023.113293↗
  7. A Lesson in Transcriptional Plasticity: Classical Identity Is Silenced, but Not Lost, in Pancreatic Ductal Adenocarcinoma Cell Lines. Co-author DOI 10.1053/j.gastro.2022.07.005↗
  8. A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer: Th… Co-author DOI 10.1097/sla.0000000000004143↗
  9. Influence of Klebsiella pneumoniae and quinolone treatment on prognosis in patients with pancreatic cancer. Co-author DOI 10.1002/bjs.12003↗
  10. Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy. Co-author DOI 10.1007/s11605-020-04897-9↗
  11. Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. Co-author DOI 10.1093/jnci/djaa073↗
  12. Transcriptomic Analysis of Laser Capture Microdissected Tumors Reveals Cancer- and Stromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-20-1039↗
  13. Hedgehog signaling promotes angiogenesis directly and indirectly in pancreatic cancer. Co-author DOI 10.1007/s10456-020-09725-x↗
  14. Variation in long-term oncologic outcomes by type of cancer center accreditation: An analysis of a SEER-Medicare population with pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2020.03.035↗
  15. Diabetes mellitus is associated with unfavorable pathologic features, increased postoperative mortality, and worse long-term survival in resected pancreatic ca… Co-author DOI 10.1016/j.pan.2019.10.007↗
  16. Primary and Metastatic Pancreatic Cancer Cells Exhibit Differential Migratory Potentials. Co-author DOI 10.1097/mpa.0000000000001459↗
  17. Evaluation of Pathologic Response on Overall Survival After Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001590↗
  18. Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003123↗
  19. Neoplastic-Stromal Cell Cross-talk Regulates Matrisome Expression in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-20-0439↗
  20. Main Pancreatic Duct to Parenchymal Thickness Ratio at Preoperative Imaging is Associated with Overall Survival in Upfront Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-019-08040-0↗
  21. FOLFIRINOX Versus Gemcitabine-based Therapy for Pancreatic Ductal Adenocarcinoma: Lessons from Patient-derived Cell Lines. Co-author DOI 10.21873/anticanres.14355↗
  22. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000002600↗
  23. Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges. Last author DOI 10.3748/wjg.v25.i23.2839↗
  24. New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer. Co-author DOI 10.1016/j.pan.2018.08.003↗
  25. Are Staging Computed Tomography (CT) Scans of the Chest Necessary in Pancreatic Adenocarcinoma? Co-author DOI 10.1245/s10434-018-6764-3↗
  26. Intraoperative Dexamethasone Decreases Infectious Complications After Pancreaticoduodenectomy and is Associated with Long-Term Survival in Pancreatic Cancer. Co-author DOI 10.1245/s10434-018-6827-5↗
  27. Reappraisal of Staging Laparoscopy for Patients with Pancreatic Adenocarcinoma: A Contemporary Analysis of 1001 Patients. Co-author DOI 10.1245/s10434-017-5973-5↗
  28. Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival. Co-author DOI 10.1371/journal.pone.0182855↗
  29. Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s11605-016-3108-0↗
  30. Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment. Co-author DOI 10.1158/1078-0432.ccr-15-2068↗
  31. Health Insurance Expansion and Treatment of Pancreatic Cancer: Does Increased Access Lead to Improved Care? Co-author DOI 10.1016/j.jamcollsurg.2015.09.010↗
  32. Circulating tumor cells found in patients with localized and advanced pancreatic cancer. Co-author DOI 10.1097/mpa.0000000000000324↗
  33. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Co-author DOI 10.1097/sla.0000000000000867↗
  34. Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at… Co-author DOI 10.1002/cncr.28329↗
  35. N0/N1, PNL, or LNR? The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s11605-012-1974-7↗
  36. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection? First author DOI 10.1097/sla.0b013e318263da2f↗
  37. Intraductal papillary mucinous neoplasms: does a family history of pancreatic cancer matter? Co-author DOI 10.1016/j.pan.2012.05.011↗
  38. Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Last author DOI 10.1016/j.surg.2012.05.020↗
  39. Targeting the MAGE A3 antigen in pancreatic cancer. Co-author DOI 10.1016/j.surg.2012.05.031↗
  40. Neutrophil granulocyte derived MMP-9 is a VEGF independent functional component of the angiogenic switch in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s10456-011-9207-3↗
  41. Plectin-1 as a novel biomarker for pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-10-0999↗

Closest collaborators

The 25 strongest of 114 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Keith D. Lillemoe · 34 shared papers, 2012–2025 · strength 3.33
  2. Carlos F. Fernandez-del Castillo · 25 shared papers, 2012–2025 · strength 2.15
  3. Cristina Rosa Ferrone · 25 shared papers, 2012–2024 · strength 2.10
  4. Motaz Qadan · 15 shared papers, 2018–2025 · strength 1.83
  5. Thomas P. Hank · 11 shared papers, 2020–2025 · strength 1.52
  6. Andrew Scott Liss · 12 shared papers, 2015–2025 · strength 1.30
  7. Carlos Fernández-del Castillo · 9 shared papers, 2020–2024 · strength 1.15
  8. Mari A. Mino-Kenudson · 12 shared papers, 2011–2025 · strength 0.99
  9. David Tsai Ting · 9 shared papers, 2015–2025 · strength 0.92
  10. Theodore Sunki Hong · 10 shared papers, 2013–2023 · strength 0.83
  11. Marta Sandini · 6 shared papers, 2018–2025 · strength 0.72
  12. David P. Ryan · 9 shared papers, 2013–2023 · strength 0.70
  13. Oliver Strobel · 4 shared papers, 2022–2025 · strength 0.69
  14. Jennifer Yon-Li Wo · 8 shared papers, 2013–2023 · strength 0.69
  15. Vikram Deshpande · 9 shared papers, 2012–2021 · strength 0.63
  16. Sarah P. Thayer · 12 shared papers, 2011–2020 · strength 0.59
  17. Klaus Sahora · 3 shared papers, 2023–2025 · strength 0.57
  18. Martin Schindl · 3 shared papers, 2023–2025 · strength 0.57
  19. Carl-Stephan Leonhardt · 3 shared papers, 2023–2025 · strength 0.57
  20. Kim C. Honselmann · 5 shared papers, 2017–2025 · strength 0.51
  21. Cristina R. Ferrone · 4 shared papers, 2017–2025 · strength 0.50
  22. Colin D. Weekes · 4 shared papers, 2021–2023 · strength 0.47
  23. Jon Michael Harrison · 3 shared papers, 2022–2025 · strength 0.47
  24. David Jérémie Birnbaum · 4 shared papers, 2020–2022 · strength 0.46
  25. Ulla Klaiber · 3 shared papers, 2022–2024 · strength 0.46

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.